Literature DB >> 7980530

Characterization of contractile endothelin and angiotensin receptors in human resistance arteries: evidence for two endothelin and one angiotensin receptor.

M R Tschudi1, T F Lüscher.   

Abstract

Endothelin-1 (ET-1) and angiotensin II (AII) are potent vasoconstrictor hormones which regulate tissue perfusion and blood pressure. We pharmacologically characterized endothelin and angiotensin receptors mediating contractions of human mammary resistance arteries in myographs for isometric tension recording. ET-1 caused potent contractions. The concentration response curve was shifted to the right by ETA antagonist FR 139317, but a high sensitivity, low efficacy component remained. After incubation with ETB agonist sarafotoxin (S6c) this component of the concentration response curve resistant to FR 139317 disappeared. The ETA/ETB-receptor antagonist bosentan shifted the entire concentration response curve to the right. AI and AII caused marked contractions. The effects of AI were reduced by the ACE inhibitor benazeprilat, while those of AII were prevented by valsartan, an AT1 antagonist. In summary, in human resistance arteries, contractions to ET-1 are mediated by ETA- and ETB-receptors while those to AII are exclusively mediated by AT1-receptors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7980530     DOI: 10.1006/bbrc.1994.2514

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Endothelial dysfunction: the role and impact of the renin-angiotensin system.

Authors:  T F Lüscher
Journal:  Heart       Date:  2000-09       Impact factor: 5.994

Review 2.  Valsartan. A review of its pharmacology and therapeutic use in essential hypertension.

Authors:  A Markham; K L Goa
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

3.  The mechanism of cryoinjury: In vitro studies on human internal mammary arteries.

Authors:  E Müller-Schweinitzer; W Brett; H R Zerkowski; W E Haefeli
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

Review 4.  Endothelial dysfunction and hypertension.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 5.  The clinical potential of endothelin receptor antagonists in cardiovascular medicine.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

6.  Plasticity of contractile endothelin-B receptors in human arteries after organ culture.

Authors:  M Adner; L Cantera; F Ehlert; L Nilsson; L Edvinsson
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

Review 7.  Endothelin in cardiovascular control: the role of endothelin antagonists.

Authors:  R R Wenzel; P Czyborra; T Lüscher; T Philipp
Journal:  Curr Hypertens Rep       Date:  1999 Feb-Mar       Impact factor: 5.369

8.  Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men.

Authors:  J C Spratt; J Goddard; N Patel; F E Strachan; A J Rankin; D J Webb
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

Review 9.  The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?

Authors:  N S Kirkby; P W F Hadoke; A J Bagnall; D J Webb
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

10.  Increased expression of endothelin ET(B) and angiotensin AT(1) receptors in peripheral resistance arteries of patients with suspected acute coronary syndrome.

Authors:  Ivan Dimitrijevic; Ulf Ekelund; Marie-Louise Edvinsson; Lars Edvinsson
Journal:  Heart Vessels       Date:  2009-11-22       Impact factor: 2.037

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.